The designation follows Phase III HARMONi-GI1 results showing significantly improved overall survival versus durvalumab plus ...

Part of Phase III of the National Precision Medicine programme, the study will connect genomic and health data from nearly ...

The National Comprehensive Cancer Network® (NCCN®) announced the signing of a new agreement with the Viet Nam National Cancer ...

Abbott will commercialise Plosbrio®, a second brand of Ozempic® developed and manufactured by Novo, in Singapore and other ...

Figure 1. Ownership flow for the 21 APAC-origin ADCs in Phase 3 or registrational trials. Left: originator. Right: holder of ...

ASKA gains exclusive Japanese rights to MHB018A, with Minghui receiving $110 million upfront and eligibility for up to $330 ...

Differentia Bio, a developer of AI-powered human disease digital twins, announced that therapeutic mechanisms identified by ...

Mr Ng Tian Chong, Chief Executive Officer, Singtel Singapore; Professor Yeoh Khay Guan, Chief Executive, NUHS; and Mr Daniel ...

Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acquisition of a specialized clinical ...

Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced a ...

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US ...

JH2-selective TYK2 inhibitor meets primary and key secondary endpoints, with over 80% of patients achieving clear or almost ...